FDA Category 1 vs Category 2 Peptides: The 2026 Update Explained

In late 2023, the FDA placed 19 widely used peptides on its Category 2 list, effectively blocking compounding pharmacies from preparing them. In February 2026, approximately 14 of those peptides were restored to Category 1 — reopening the compounding market. Here's what the categories mean, which peptides moved, and what buyers need to do now.

What Are Category 1 and Category 2?

The FDA maintains a bulk drug substances list that determines which compounds 503A and 503B pharmacies can use in compounding. The categories work as follows:

• Category 1: Substances the FDA has evaluated and determined are eligible for use in compounding. Compounding pharmacies can use these substances to prepare medications under applicable regulations.
• Category 2: Substances the FDA has determined raise significant safety or regulatory concerns. When a substance is placed on Category 2, compounding pharmacies are effectively prohibited from using it.
• Category 3: Substances for which the FDA needs additional information before making a determination.

The 2023 Restrictions

The original Category 2 placement in late 2023 affected 19 peptides that were widely used in clinical practice. The restricted compounds included: BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank, Semax, GHK-Cu, KPV, MOTS-c, Epithalon, Dihexa, and several others.

The restrictions created immediate supply chain disruption. Compounding pharmacies had to stop preparing these compounds, clinics lost access to treatments they'd been prescribing, and the grey-market research peptide industry expanded as patients sought alternatives outside the regulated system.

The February 2026 Reversal

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced the restoration of approximately 14 peptides to Category 1. The announcement cited a review of safety data and the public health implications of restricting access to compounds with established clinical use.

Peptides Confirmed Restored to Category 1

• BPC-157
• TB-500 (Thymosin Beta-4)
• Thymosin Alpha-1
• GHK-Cu
• Selank
• Semax
• CJC-1295
• Ipamorelin
• KPV
• AOD-9604
• MOTS-c
• Epithalon

What This Means for Buyers

The restoration to Category 1 means compounding pharmacies can once again prepare these peptides, but several practical considerations apply:

• API sourcing: Pharmacies need to re-establish or establish new relationships with API suppliers. The supply chain disruption of the Category 2 period may have caused some suppliers to exit the market.
• Quality verification: With renewed demand, the market may see an influx of lower-quality API suppliers. COA verification and supplier qualification processes are more important than ever.
• Regulatory monitoring: Category designations can change. Buyers should monitor FDA announcements and consider this regulatory risk in their procurement planning.
• State-level variance: Some state boards of pharmacy may maintain their own restrictions independent of federal Category designations. Confirm your state's position before procurement.

Timeline of Events

Date	Event	Impact
Late 2023	FDA places 19 peptides on Category 2	Compounding of listed peptides effectively prohibited
2024	Industry advocacy and legal challenges	Multiple organizations petition for review
January 2025	New administration takes office	Regulatory review priorities shift
February 27, 2026	HHS announces Category 1 restoration	~14 peptides eligible for compounding again
March-April 2026	Supply chain rebuilding	Pharmacies re-qualifying suppliers; demand surges

Remaining Category 2 Peptides

Not all 19 original Category 2 peptides were restored. Several compounds remain restricted as of April 2026. Buyers should verify the current status of any peptide before procurement — the FDA's bulk drug substances list is the definitive reference and should be checked directly rather than relying on secondary sources that may not reflect the most recent changes.

Future Regulatory Risk

The Category 1 restoration does not guarantee permanent access. Category designations can change with changing administrations, new safety data, or shifting FDA enforcement priorities. Prudent procurement planning should include:

• Monitoring FDA announcements for any proposed Category changes
• Maintaining safety stock of critical compounds (4-8 weeks minimum)
• Diversifying peptide programs so no single compound represents an existential business risk if re-restricted
• Building relationships with industry advocacy organizations that track and influence regulatory developments
• Documenting clinical outcomes data that can support the case for continued compounding access

For the complete regulatory framework including 503A/503B compliance requirements, see our Peptide Regulatory Compliance Guide.